PAY ATTENTION: Got a Minute? Complete Our Quick Survey About Legit.ng Today! The price of Arabica coffee hit the highest level since 1977 on Wednesday, approaching a record high as drought in top producer Brazil this year hits supplies. A pound (453.6 grams) of Arabica beans listed in New York struck 320.10 US cents, extending the commodity's rally over 2024. The all-time high is 337.50 US cents, seen in 1977. Brazil, the world's largest coffee producer, faced a record-breaking drought this year which has raised significant concerns for 2025/2026 crops amid already tight supplies. This is despite "significant rains" in October, leading to an "excellent flowering", according to Guilherme Morya, senior analyst at Rabobank. He added that farmers were selling less than was needed to meet demand. PAY ATTENTION : Standing out in social media world? Easy! "Mastering Storytelling for Social Media" workshop by Legit.ng. Join Us Live! Analysts said that price support came also from geopolitical factors such as disruptions to shipping in the Red Sea, potential US tariffs and future European Union regulation on deforestation. "It is clearer and clearer that this (supply situation) is going to have a significant impact on the consumer," John Plassard, senior asset specialist at Mirabaud group, told AFP. Read also Saudi 2025 budget sees lower deficit on spending trims Companies are preparing to negotiate their coffee contracts early next year, with food giants like Nestle set to pass on price increases to customers. The Swiss group announced this month that it would increase prices and reduce the size of its coffee bags to protect margins. Keep on buying In London , some coffee drinkers approached by AFP on Wednesday vowed to keep on buying their beans, but owing to recent price hikes added that they had already begun to buy fewer cups in cafes. "I've noticed that the prices have gone up," said Julie, 34, as she held a cup of coffee not long purchased from a coffee shop. "I prefer to buy packs and brew it at home. It's rare for me to buy it in the shop, but it used to be more frequent." Nicky, 26, said she was not ready to give up purchasing cups of coffee in stores. Read also Asian markets begin week on front foot, bitcoin rally stutters "I would still pay for it. Maybe that's me being financially reckless." She described coffee drinking as "a lifestyle, it's how people start their day". Vietnam has also faced supply concerns this year for its cheaper Robusta bean that is used for instant coffee, as the country faced dryness during the growing period. Robusta, listed in London, is trading at around $5,200 per tonne, after reaching a record price of $5,829 in mid-September. PAY ATTENTION : Legit.ng Needs Your Opinion! That's your chance to change your favourite news media. Fill in a short questionnaire Source: AFPThe Juniata-Southern Lehigh football game, a PIAA Class 4A quarterfinal playoff game scheduled for 7 p.m. Friday at Shamokin High School, was postponed due inclement wintry weather. • Sign up for PennLive’s daily high school sports newsletter More High School Sports Pa. high school football scoreboard: Live updates from the state’s top-ranked teams (11/22/24) Pennsylvania football records in play for two Mid-Penn Conference standouts District 3 5A football championship Bishop McDevitt vs. Exeter: Watch here Pa. High School Football Report podcast: The countdown to National Signing Day is on
HAL set to begin trials of LAC Tejas Mk1A in January 2025: ReportsAI adoption is surging — but humans still need to be in the loop, say software developers from Meta, Amazon, Nice, and more
Senators begin filing bills for Florida’s 2025 legislative sessionZebra Technologies Q3: Broad Demand Recovery
Toll Brothers Apartment Living and Equity Residential Celebrate the Grand Opening of Lyle, a New Luxury Apartment Community in Dallas, Texas
Amentum Reports Fiscal Year 2024 Results and Affirms its Fiscal Year 2025 GuidanceKash Patel: The die-hard loyalist
Global Times: China Advances Foreign Trade With Higher-Quality Products Exported And More Imports From LdcsMichael Croley | (TNS) Bloomberg News In the old days of 2016, when golfers visited the Dormie Club in West End, North Carolina — 15 minutes from the hotbed of American golf, Pinehurst — they were greeted by a small, single-wide trailer and a rugged pine straw parking lot. That trailer is now long gone. A gate has been installed at the club’s entrance and a long driveway leads to a grand turnaround that sweeps you past a new modern clubhouse that’s all right angles, with floor-to-ceiling glass. Seconds after you exit your car, valets are zipping up in golf carts, taking your name, then your bags, handing you keys to your own golf cart, and then zipping off to drop your luggage in the four-bedroom cottage where you’ll stay. A short walk past an expansive putting green you’ll find the pro shop — and then you’ll see the club’s most elegant feature: its golf course. The changes have all come about because Dormie Club was acquired in 2017 by the Dormie Network, a national group that owns seven private golf facilities from Nebraska to New Jersey. (“Dormie” is a word for being ahead in golf — the names were coincidences.) A key to the network’s success has been its ability to find clubs ripe for acquisition, with outstanding golf courses and existing on-site lodging or the room to build it, says Zach Peed, president of the company and its driving force. After investing in Arbor Links Golf Club in Nebraska City, Nebraska, in late 2015, Peed believed he saw an opening in the golf market: a new model of hospitality for traveling professionals who wanted a pure golf experience that eschewed the pools and pickleball courts of their home clubs. His clubs would become dream golf-only getaways for avid players and their pals. “Dormie Network’s concept was sparked by having played competitive golf in college, combined with an element of experiencing and understanding hospitality,” says Peed. “It made sense to blend the two to create golf trips that had more value than just playing golf. We want genuine hospitality to help create unforgettable memories and new friendships.” Part of that formula has been in the lodging strategy; in North Carolina, 15 four-bedroom cottages now are a short golf cart ride from the main clubhouse. In each, golfers all have their own king-size bed and en suite bathroom. A large common room is dominated by a flatscreen television along with a well-stocked bar and snacks. That ability to be both social, or tucked away in your room, extends to the expansive new clubhouse, where a high-ceilinged bar area with blond wood creates an inviting space for dining and drinking, and several hideaway rooms allow for more private diners with just your group. So far, their commitment to hospitality has been helping them expand in both membership and club usage in the increasingly competitive market for traveling golfers. Major players such as Bandon Dunes, Pinehurst Resort, and the Cabot Collection have created — or renovated — a new paradigm where golfers get dining and lodging that’s as showcase-worthy as the courses they play. Comfortable sheets and options beyond pub food aren’t luxuries anymore, but staples for many group trips. Dormie has answered that call by focusing on both the big details and the small ones, like having the dew wiped off each golf cart at dawn outside guest cottages before the day begins or having a tray of cocktails delivered to golfers as their final putt falls on the 18th green. These touches may seem over-the-top, but they stand out in a world where golf travel is increasingly popular — and expensive — after the pandemic lockdowns. Since 2020 there has been an explosion in participation in the sport, with new golfers picking up the game and avid golfers playing more: According to the National Golf Foundation, a record 531 million rounds were played in 2023, surpassing the high of 529 million set in 2021. Supreme Golf, a public golf booking website, reports in its latest analysis that the average cost of a tee time has increased to $49 in 2024 from $38 in 2019, a 30% increase. Those cost increases are also on par (pun intended) with the costs of private clubs and initiation fees during that same period, where membership rosters that were dwindling pre-COVID now have waitlists 50 to 60 people deep, according to Jason Becker, co-founder and chief executive officer of Golf Life Navigators, which matches homebuyers with golf course communities. “There’s been an absolute run on private golf. If we use southwest Florida as an example, where there are 158 golf communities, this time last November, only five had memberships available,” he said. That inability to find a club close to home has pushed avid golfers to look farther afield, choosing national memberships at clubs that require traveling, usually via plane, to play. Dormie has capitalized on this growing segment, offering two types of memberships: First, a national membership, where members pay an initiation fee and monthly dues just as they would at a local club, but instead of one club they have access to seven. The second option is a signature membership for companies, “which allows businesses to use our properties for entertainment needs and requires a multiyear commitment,” Peed says. The network also offers a limited number of regional memberships for those living within a certain distance of one of its clubs. Dormie Network declined to provide the cost of memberships or monthly dues and wouldn’t give membership numbers, but the clubs are structured to lodge roughly 60 golfers, max, on-site at any given property at any time. The total number of beds across the network’s portfolio of properties has increased from 84 in 2019 to 432 today. It saw a jump from 10,000 room nights in 2019 to 48,000 in 2023. This September, Dormie opened GrayBull in Maxwell, in Nebraska’s, Sandhills region. Dormie Network tabbed David McLay Kidd to build the course, who also built the original course at Oregon’s famed Bandon Dunes. Kidd says of the property GrayBull sits on, “It’s like the Goldilocks thing: not too flat, not too steep. It’s kind of in a bowl that looks inwards, and there are no bad views.” That kind of remote destination, where the long-range views are only Mother Nature or other golf holes, is what drives many traveling golfers these days. Peed says his team leaned on years of knowledge from Dormie’s acquisitions as they built GrayBull, which started construction in 2022. “We had an understanding of how our members and guests use the clubs that allowed us to take a blank canvas in the Sandhills of Nebraska and combine all of the greatest aspects of each Dormie property into one.” ©2024 Bloomberg L.P. Visit bloomberg.com. Distributed by Tribune Content Agency, LLC.Liverpool beat holders Real Madrid with Aston Villa denied win against Juventus
Harry Kane becomes the fastest player to score 50 goals in the BundesligaNoneCNBC Daily Open: Expectations can be an irrational thing. Just look at Nvidia
Trump selects longtime adviser Keith Kellogg as special envoy for Ukraine and Russia
16-year-old Hockey Player, Colin Brown, Tragically Passes Away During Shooting IncidentPeraso Inc. (NASDAQ: PRSO) Among ONDS, JOBY, ACHR, UMAC with Game-Changing Drone Technology to Watch Now! 12-16-2024 10:12 PM CET | Business, Economy, Finances, Banking & Insurance Press release from: ABNewswire Millimeter wave (mmWave) innovation and a small float spark investor excitement as Peraso Inc. (NASDAQ: PRSO) captures attention in the drone tech space. Peraso Inc. (NASDAQ: PRSO), a leader in millimeter wave (mmWave) technology, is making headlines with its cutting-edge innovations in wireless connectivity, specifically for surveillance drones. Leveraging high-speed, low-latency links, Peraso's technology is ideal for drones that require real-time data transfer, making it a game-changer in sectors like security, logistics, and remote monitoring. With a remarkably low float of just 3.9 million shares, Peraso Inc. (NASDAQ: PRSO) has become a high-potential stock to watch. To put this in perspective, the float is nearly 20 times smaller than that of Ondas Holdings Inc. (NASDAQ: ONDS), which recently experienced a massive rally, climbing from $0.80 to $1.50 in a matter of weeks. This kind of volatility could signal a similar breakout opportunity for Peraso. The global drone market continues to expand at an unprecedented pace, driven by demand for advanced applications in both civilian and military sectors. Peraso's mmWave technology is uniquely positioned to serve this booming market, as it provides the ultra-fast data speeds and minimal latency essential for drones used in real-time surveillance, precision delivery, and beyond. Investors are Taking NoteThe combination of a small float, advanced technology, and growing market demand has led to increased interest from retail and institutional investors alike. Stocks with a limited float like Peraso Inc. (NASDAQ: PRSO) often see significant price movements when demand spikes, offering the potential for sharp gains in a short timeframe. Analysts Are Watching the Drone Boom The adoption of mmWave technology is becoming a cornerstone of the next generation of drone communication systems. With industries increasingly turning to autonomous solutions, companies like Peraso Inc. (NASDAQ: PRSO) are set to ride the wave of this transformation. As Peraso Inc. (NASDAQ: PRSO) continues to innovate and expand its influence in the drone tech sector, all eyes are on Peraso Inc. (NASDAQ: PRSO) as a potential breakout stock. With its affordable price point, compelling technology, and bullish market indicators, this is one ticker investors won't want to miss.Stay tuned for updates as the drone mystery unfolds and Peraso Inc. (NASDAQ: PRSO makes its mark in the world of advanced mmWave technology.Several stocks in the drone sector, including Peraso Inc. (NASDAQ: PRSO), Joby Aviation Inc. (NYSE: JOBY), Archer Aviation Inc. (NYSE: ACHR), Unusual Machines Inc. (NYSE: UMAC), Mobilicom Limited (NASDAQ: MOB), and Ondas Holdings Inc. (NASDAQ: ONDS), have demonstrated notable momentum and deserve a spot on every investor's radar. Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website. Media Contact Company Name: The Street Reports Contact Person: Editor Email:Send Email [ https://www.abnewswire.com/email_contact_us.php?pr=peraso-inc-nasdaq-prso-among-onds-joby-achr-umac-with-gamechanging-drone-technology-to-watch-now ] Country: United States Website: http://www.thestreetreports.com This release was published on openPR.Kickboxing Meets Elegance in London’s Colosseum Tournament 45
President-elect Donald Trump has filled the key posts for his second term in office, prioritizing loyalty to him after he felt bruised and hampered by internal squabbling during his first term. Some of his choices could face difficult confirmation fights in the Senate, even with Republicans in control, and one candidate has already withdrawn from consideration. Former Florida Rep. Matt Gaetz was Trump's initial pick for attorney general, but he ultimately withdrew following scrutiny over a federal sex trafficking investigation he was embroiled in. Here's a look at Trump's choices: Trump would turn a former critic into an ally as the nation's top diplomat. Rubio , 53, is a noted hawk on China, Cuba and Iran, and was a finalist to be Trump's running mate before the slot went to JD Vance. Rubio is vice chairman of the Senate Intelligence Committee and a member of the Senate Foreign Relations Committee. His selection punctuates the hard pivot Rubio has made with Trump, whom the senator once called a “con man" during his own unsuccessful campaign for the 2016 Republican presidential nomination. Their relationship improved dramatically while Trump was in the White House. Hegseth , 44, was a co-host of Fox News Channel’s “Fox and Friends Weekend” and had been a contributor with the network since 2014. He developed a friendship with Trump, who made regular appearances on the show. Hegseth served in the Army National Guard from 2002 to 2021, deploying to Iraq in 2005 and Afghanistan in 2011 and earning two Bronze Stars. He lacks senior military and national security experience and would oversee global crises ranging from Europe to the Middle East. A woman told police that she was sexually assaulted in 2017 by Hegseth after he took her phone, blocked the door to a California hotel room and refused to let her leave, according to a detailed investigative report recently made public. Hegseth told police at the time that the encounter had been consensual and has denied any wrongdoing. Bessent , 62, is a former money manager for George Soros , a big Democratic donor, and an advocate for deficit reduction . He founded the hedge fund Key Square Capital Management after having worked on and off for Soros Fund Management since 1991. If confirmed by the Senate, Bessent would be the nation’s first openly gay treasury secretary. He told Bloomberg in August that he decided to join Trump’s campaign in part to attack the mounting U.S. national debt. That would include slashing government programs and other spending. Gabbard, 43, is a former Democratic House member from Hawaii who has been accused of echoing Russian propaganda. She unsuccessfully sought the party’s 2020 presidential nomination and left the party in 2022. Gabbard endorsed Trump in August and campaigned often with him. Gabbard has served in the Army National Guard for more than two decades and deployed to Iraq and Kuwait. If confirmed she would come to the role as an outsider compared to her predecessor. The current director, Avril Haines, spent several years in top national security and intelligence positions. Bondi , 59, was Florida's first female attorney general, serving between 2011 and 2019. She was on Trump’s legal team during his first impeachment trial in 2020. Considered a loyalist , Bondi also has served with the America First Policy Institute, a Trump-allied group that has helped lay the groundwork for his future administration. Bondi was among a group of Republicans who showed up to support Trump at his hush-money criminal trial in New York that ended in May with a conviction on 34 felony counts. A fierce defender of Trump, she also frequently appeared on Fox News and has been critical of the criminal cases against him. The Republican U.S. House member narrowly lost her reelection bid on Nov. 5 but had received strong backing from union members in her district. As a potential labor secretary, Chavez-DeRemer would oversee the department's workforce and budget and put forth priorities that affect workers’ wages, health and safety, ability to unionize, and employer’s rights to fire employers, among other responsibilities. Chavez-DeRemer is one of a few House Republicans to endorse the “Protecting the Right to Organize” or PRO Act that would allow more workers to conduct organizing campaigns and penalize companies that violate workers’ rights. The act would also weaken “right-to-work” laws in more than half the states. Lutnick heads the brokerage and investment bank Cantor Fitzgerald and is a cryptocurrency enthusiast. He is co-chair of Trump's transition operation, charged along with Linda McMahon, a former wrestling executive who previously led Trump’s Small Business Administration, with helping the president-elect fill key jobs in his second administration. As secretary, Lutnick would play a key role in carrying out Trump's plans to raise and enforce tariffs. He would oversee a sprawling Cabinet department whose oversight ranges from funding new computer chip factories and imposing trade restrictions to releasing economic data and monitoring the weather. Noem is a well-known conservative who used her two terms as South Dakota's governor to vault to a prominent position in Republican politics. During the COVID-19 pandemic, Noem did not order restrictions like other states, instead declaring South Dakota “open for business.” More recently, Noem faced sharp criticism for writing in her memoir about shooting and killing her dog. She is set to lead a department crucial to the president-elect’s hardline immigration agenda as well as other missions. Homeland Security oversees natural disaster response, the U.S. Secret Service and Transportation Security Administration agents who work at airports. Ratcliffe , a former U.S. House member from Texas, was director of national intelligence during the final year and a half of Trump’s first term. He led U.S. government’s spy agencies during the coronavirus pandemic. If confirmed, Ratcliffe will have held the highest intelligence positions in the U.S. Kennedy , 70, ran for president as a Democrat, then as an independent before he dropped out and then endorsed Trump . He's the son of Democratic icon Robert F. Kennedy, who was assassinated in 1968 during his own presidential campaign. Kennedy's nomination alarmed people who are concerned about his record of spreading unfounded fears about vaccines . For example, he has long advanced the debunked idea that vaccines cause autism. Rollins , 52, is president and CEO of the America First Policy Institute, a group helping to lay the groundwork for Trump's second administration. She is a Texas attorney who was Trump's domestic policy adviser and director of his office of American innovation during his first term. Rollins previously was an aide to former Texas Gov. Rick Perry , who also served in Trump's first term. Rollins also ran the Texas Public Policy Foundation. Duffy is a former House member from Wisconsin who was one of Trump's most visible defenders on cable news. Duffy served in the House for nearly nine years , sitting on the Financial Services Committee and chairing the subcommittee on insurance and housing. He left Congress in 2019 for a TV career and has been the host of “The Bottom Line” on Fox Business. Before entering politics, Duffy was a reality TV star on MTV, where he met his wife, “Fox and Friends Weekend” co-host Rachel Campos-Duffy. They have nine children. Collins is a former Republican congressman from Georgia who gained recognition for defending Trump during his first impeachment trial. Trump was impeached for urging Ukraine to investigate Joe Biden in 2019 during the Democratic presidential campaign, but was acquitted by the Senate. Collins also served in the armed forces himself. He is a chaplain in the United States Air Force Reserve Command. The North Dakota governor , 68, is a former Republican presidential primary contender who endorsed Trump after he dropped out of the running. Burgum then became a serious contender to be Trump’s vice presidential choice in part because of his executive experience and business savvy. He also has close ties to deep-pocketed energy industry CEOs. Trump said Burgum would chair a new National Energy Council and have a seat on the National Security Council, which would be a first for the Interior secretary. A campaign donor and CEO of Denver-based Liberty Energy, Wright is a vocal advocate of oil and gas development, including fracking — a key pillar of Trump’s quest to achieve U.S. “energy dominance” in the global market. He also has been one of the industry’s loudest voices against efforts to fight climate change. Wright said the climate movement around the world is “collapsing under its own weight.” The Energy Department is responsible for advancing energy, environmental and nuclear security of the United States. McMahon, a billionaire professional wrestling mogul , would make a return appearance in a second Trump administration. She led the Small Business Administration from 2017 to 2019 in Trump’s first term and twice ran unsuccessfully in Connecticut as a Republican candidate for the U.S. Senate. She served on the Connecticut Board of Education for a year starting in 2009 and has spent years on the board of trustees for Sacred Heart University. She has expressed support for charter schools and school choice. Zeldin does not appear to have any experience in environmental issues, but is a longtime supporter of the former president. The 44-year-old former U.S. House member from New York wrote on X , “We will restore US energy dominance, revitalize our auto industry to bring back American jobs, and make the US the global leader of AI" and "we will do so while protecting access to clean air and water.” Trump often attacked the Biden administration’s promotion of electric vehicles, and incorrectly referred to a tax credit for EV purchases as a government mandate. Trump also often said his administration would “drill, baby, drill,” referring to his support for expanded petroleum exploration. Turner is a former NFL player and White House aide. He ran the White House Opportunity and Revitalization Council during Trump’s first term in office. Trump, in a statement, credited Turner, the highest-ranking Black person he’s yet selected for his administration, with “helping to lead an Unprecedented Effort that Transformed our Country’s most distressed communities.” Greer is a partner at King & Spalding, a Washington law firm. If confirmed by the Senate, he would be responsible for negotiating directly with foreign governments on trade deals and disputes, as well as memberships in international trade bodies such as the World Trade Organization. He previously was chief of staff to Robert Lighthizer, who was the trade representative in Trump's first term. Wiles , 67, was a senior adviser to Trump’s 2024 presidential campaign and its de facto manager. She has a background in Florida politics , helping Ron DeSantis win his first race for Florida governor. Six years later, she was key to Trump’s defeat of him in the 2024 Republican primary. Wiles’ hire was Trump’s first major decision as president-elect and one that could be a defining test of his incoming administration considering her close relationship with him. Wiles is said to have earned Trump’s trust in part by guiding what was the most disciplined of Trump’s three presidential campaigns. Waltz is a three-term Republican congressman from east-central Florida. A former Army Green Beret , he served multiple tours in Afghanistan and worked in the Pentagon as a policy adviser when Donald Rumsfeld and Robert Gates were defense chiefs. He is considered hawkish on China, and called for a U.S. boycott of the 2022 Winter Olympics in Beijing due to its involvement in the origin of COVID-19 and its mistreatment of the minority Muslim Uighur population. Hassett, 62, is a major advocate of tax cuts who was chairman of the Council of Economic Advisers in the first Trump term. In the new role as chairman of the National Economic Council, Trump said Hassett will play an important role in helping American families recover from inflation as well as in renewing and improving tax cuts Trump enacted in 2017, many of which are set to expire after 2025. Homan, 62, has been tasked with Trump’s top priority of carrying out the largest deportation operation in the nation’s history. He led the U.S. Immigration and Customs Enforcement in Trump's first administration. Democrats have criticized Homan for defending Trump’s “zero tolerance” policy on border crossings in the first term, which led to the separation of thousands of parents and children seeking asylum at the border. Vought, 48, held the position during Trump’s first presidency. He the founded the Center for Renewing America, a think tank that describes its mission as “renew a consensus of America as a nation under God.” Vought also was closely involved with Project 2025 , a conservative blueprint for Trump’s second term that Trump tried to distance himself from during the campaign. Miller, an immigration hardliner , was a vocal spokesperson during the presidential campaign for Trump’s priority of mass deportations. The 39-year-old was a senior adviser during Trump’s first term. Miller has been a central figure in some of Trump’s policy decisions, notably his move to separate thousands of immigrant families. Trump argued throughout the campaign that the nation’s economic, national security and social priorities could be met by deporting people living illegally in the U.S. Scavino was an adviser in all three of the president-elect's campaigns and was described by the transition team as one of “Trump’s longest serving and most trusted aides." He will be deputy chief of staff and assistant to the president. Scavino previously ran Trump’s social media profile in the White House. Blair was political director for Trump’s 2024 campaign and for the Republican National Committee. He will be deputy chief of staff for legislative, political and public affairs and an assistant to the president. Blair was key to Trump’s economic messaging during his winning White House comeback campaign. Budowich is a veteran Trump campaign aide who launched and directed Make America Great Again, Inc., a super PAC that supported Trump’s 2024 campaign. He will be deputy chief of staff for communications and personnel and assistant to the president. Leavitt , 27, was Trump's campaign press secretary and currently a spokesperson for his transition. She would be the youngest White House press secretary in history. Leavitt worked in the White House press office during Trump's first term. In 2022, she ran for Congress in New Hampshire, winning a 10-way Republican primary before losing to Democratic Rep. Chris Pappas. McGinley was Cabinet secretary during Trump's first administration and was outside legal counsel for the Republican National Committee's election integrity effort during the 2024 campaign. The 67-year-old Witkoff is the president-elect's golf partner and they were golfing at Trump's club in West Palm Beach, Florida, on Sept. 15, when the former president was the target of a second attempted assassination. Trump also named Witkoff co-chair, with former Georgia Sen. Kelly Loeffler, of his inaugural committee. Kellogg , 80, is a highly decorated retired three-star general and one of the architects of a staunchly conservative policy book that lays out an “America First” national security agenda for Trump's second term. He has long been Trump’s top adviser on defense issues and served as national security adviser to Vice President Mike Pence . Kellogg also was chief of staff of the National Security Council under Trump and stepped in as an acting national security adviser for Trump after Michael Flynn resigned the post. Huckabee is a staunch defender of Israel and his intended nomination comes as Trump has promised to align U.S. foreign policy more closely with Israel's interests. Huckabee, who ran unsuccessfully for the Republican presidential nomination in 2008 and 2016, has been a popular figure among evangelical Christian conservatives, many of whom support Israel due to Old Testament writings that Jews are God’s chosen people and that Israel is their rightful homeland. Huckabee has rejected a Palestinian homeland in territory occupied by Israel. His daughter, Sarah Huckabee Sanders, served as White House press secretary in Trump's first term. Stefanik, 40, is a U.S. representative from New York and one of Trump's staunchest defenders dating to his first impeachment trial. She was elected chair of the House Republican Conference in 2021, the third-highest position in House leadership, after then-Rep. Liz Cheney was removed from the post after she publicly criticized Trump for falsely claiming he won the 2020 election. Stefanik’s questioning of university presidents over antisemitism on their campuses helped lead to two of those presidents resigning, further raising her national profile. A former acting attorney general during Trump's first administration and tight end on the University of Iowa football team, Whitaker , 55, has a background in law enforcement but not in foreign policy. A fierce Trump localist, Whitaker, is also a former U.S. attorney in Iowa and served as acting attorney general between November 2018 and February 2019 without Senate confirmation, until William Barr was confirmed for the role. That was when special counsel Robert Mueller’s investigation into Russian election interference was drawing to a close. Whitaker also faced questions about his past business dealings, including his ties to an invention-promotion company that was accused of misleading consumers. A Republican congressman from Michigan who served from 1993 to 2011, Hoekstra was ambassador to the Netherlands during Trump's first term. Oz , 64, is a former heart surgeon who hosted “The Dr. Oz Show,” a long-running daytime TV talk show. He ran unsuccessfully for the U.S. Senate as the Republican nominee in 2022 and is an outspoken supporter of Trump, who endorsed Oz’s bid for elected office. Makary is a Johns Hopkins surgeon and author who argued against pandemic lockdowns. He routinely appeared on Fox News during the COVID-19 pandemic and wrote opinion articles questioning masks for children. He cast doubt on vaccine mandates but supported vaccines generally. Makary also cast doubt on whether booster shots worked, which was against federal recommendations on the vaccine. Nesheiwat is a general practitioner who serves as medical director for CityMD, a network of urgent care centers in New York and New Jersey. She has been a contributor on Fox News. Weldon is a former Florida congressman who recently ran for a Florida state legislative seat and lost; Trump backed Weldon’s opponent. In Congress, Weldon weighed in on one of the nation’s most heated debates of the 1990s over quality of life and a right-to-die and whether Terri Schiavo, who was in a persistent vegetative after cardiac arrest, state should have been allowed to have her feeding tube removed. He sided with the parents who did not want it removed. Bhattacharya , 56, is a critic of pandemic lockdowns and vaccine mandates. As head of the NIH, the leading medical research agency in the United States, Trump said Bhattacharya would work with Kennedy Jr. to direct U.S. medical research and make important discoveries that will improve health and save lives. Bhattacharya is professor at Stanford University School of Medicine and was one of three authors of the Great Barrington Declaration, an October 2020 open letter maintaining that lockdowns during the COVID-19 pandemic were causing irreparable harm. Gaetz, 42, withdrew from consideration to become the top law enforcement officer of the United States amid fallout over a federal sex trafficking investigation that cast doubt on his ability to be confirmed by the Senate. In choosing Gaetz, Trump had passed over more established lawyers whose names had been floated as possible contenders for the job. Gaetz resigned from Congress after Trump announced him on Nov. 13. The House Ethics Committee has been investigating an allegation that he paid for sex with a 17-year-old. Gaetz has denied wrongdoing. Associated Press writers Colleen Long, Zeke Miller, Farnoush Amiri, Lolita C. Baldor, Jill Colvin, Matthew Daly, Edith M. Lederer, Adriana Gomez Licon, Lisa Mascaro, Chris Megerian, Michelle L. Price, Will Weissert and Darlene Superville contributed to this report.What happens when 'The Simpsons' join 'Monday Night Football'? Find out during Bengals-CowboysGeorgia QB Carson Beck takes hit on throwing arm before halftime, leaving status uncertain
'Open your doors': Notre Dame re-opens after five-year refit
This Ulta Beauty Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For ThursdayX users have to pay more if they have Premium Plus subscription, Know the rates in India
THOUSAND OAKS, Calif. , Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO ® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8 , at 2 p.m. PT at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego . "Over the last decade, BLINCYTO has reshaped the treatment landscape for B-ALL, offering a critical lifeline for thousands of adult and pediatric patients," said Jay Bradner , M.D., executive vice president of Research and Development and chief scientific officer at Amgen. "These powerful new data leave us little doubt about the profound impact of this medicine for a large number of children affected by this disease. We are grateful to the Children's Oncology Group, along with the patients, families and clinical teams, for their dedication and partnership in advancing this critical study to improve the lives of children with cancer." Based on the results of the first pre-specified interim analysis for efficacy, the study met its primary endpoint of DFS and study randomization was terminated early based on the recommendation from the data and safety monitoring committee due to the benefit observed in the BLINCYTO arm compared to the chemotherapy-only arm. Overall, the 3-year DFS was 96.0% for patients treated with chemotherapy plus BLINCYTO compared to 87.9% for those treated with only chemotherapy. The hazard ratio (HR) was 0.39 [95% confidence interval (CI) 0.24-0.64], indicating a 61% reduction in the risk of disease relapse, secondary malignant neoplasm or remission death with BLINCYTO. At 3 years, more patients remained alive and cancer free when treated with BLINCYTO plus chemotherapy compared to chemotherapy alone. "The AALL1731 study results are truly practice-changing, further solidifying blinatumomab's role as the standard of care for a large number of children with B-ALL," said Sumit Gupta , M.D., Ph.D., FRCPC, co-chair of the Children's Oncology Group AALL1731 study and oncologist and clinician investigator, Division of Haematology/Oncology at The Hospital for Sick Children (SickKids) and associate professor of pediatrics at the University of Toronto . "These breakthrough data showing a significant improvement in disease-free survival are poised to bring substantial clinical value to children with newly diagnosed B-ALL." The addition of BLINCYTO to chemotherapy in standard risk patients resulted in outcomes similar to those previously achieved in only the most favorable pediatric risk subsets. Among SR-Average patients, 3-year DFS was 97.5% for patients treated with BLINCYTO compared to 90.2% for those treated with only chemotherapy (HR 0.33, CI 0.15-0.69). For SR-High patients, 3-year DFS was 94.1% for those treated with BLINCYTO compared to 84.8% for those treated with only chemotherapy (HR 0.45, 95% CI 0.24-0.85). "Relapsed ALL remains a major cause of pediatric cancer mortality, with nearly half of the relapses occurring in children with standard-risk B-ALL," said Rachel E. Rau , M.D., co-chair of the Children's Oncology Group AALL1731 study, pediatric hematologist-oncologist at Seattle Children's Hospital and associate professor of pediatrics at the University of Washington . "These findings underscore the progress made with blinatumomab in preventing relapse and support its role as a critical addition to current therapeutic strategies." Safety results are consistent with the known safety profile of BLINCYTO. BLINCYTO has demonstrated a positive balance of benefits and risks, with only 0.3% of first courses associated with Grade 3+ cytokine release syndrome (CRS) and 0.7% with seizures. A higher risk of infections was observed in the BLINCYTO arm. These results provide the first evidence supporting BLINCYTO for use in the consolidation phase in newly diagnosed pediatric Philadelphia chromosome-negative (Ph-) B-ALL patients. This groundbreaking first-in-class Bispecific T-cell Engager (BiTE ® ) therapy is now backed by additional evidence reinforcing its role in redefining a standard of care for both adult and pediatric patients, starting from one month old, regardless of measurable residual disease (MRD) status. The findings further establish BLINCYTO as a versatile first-line consolidation therapy across all ages and treatment backbones. The NCI's Cancer Therapy Evaluation Program (CTEP), which sponsored the study will share data with the U.S. Food and Drug Administration as part of their ongoing communications relating to the trial. About The Children's Oncology Group The Children's Oncology Group (childrensoncologygroup.org), a member of the NCI National Clinical Trials Network (NCTN), is the world's largest organization devoted exclusively to childhood and adolescent cancer research. The Children's Oncology Group unites over 10,000 experts in childhood cancer at more than 200 leading children's hospitals, universities and cancer centers across North America , Australia , New Zealand and Saudi Arabia in the fight against childhood cancer. Today, more than 80% of the 15,000 children and adolescents diagnosed with cancer each year in the United States are cared for at Children's Oncology Group member institutions. Research performed by Children's Oncology Group institutions over the past 50 years has transformed childhood cancer from a virtually incurable disease to one with a combined 5-year survival rate of 86%. The Children's Oncology Group's mission is to improve the cure rate and outcomes for all children with cancer. About AALL1731 (NCT03914625) The AALL1731 study was a Phase 3 randomized trial to determine if two non-sequential cycles of BLINCYTO added to chemotherapy improved disease-free survival (DFS) in children with newly diagnosed pediatric National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL). The study enrolled 4,264 newly diagnosed NCI SR B-ALL patients, of whom 2,334 were risk stratified at the end of induction therapy as either SR-Average or SR-High. At the first planned interim efficacy analysis (data cutoff June 30, 2024 ), 1,440 of the eligible and evaluable patients had been randomized. The AALL1731 study was designed and conducted independently from industry. The Cancer Therapy Evaluation Program (CTEP) of the NCI sponsored the trial and provided funding to the Children's Oncology Group to conduct the study. NCI is part of the National Institutes of Health (NIH). In addition, Amgen provided BLINCYTO and support through an NCI Cooperative Research and Development Agreement. About Acute Lymphoblastic Leukemia (ALL) ALL, also known as acute lymphoblastic leukemia, is a fast-growing type of blood cancer that develops in the bone marrow and can sometimes spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system. ALL is a rare disease, with an estimated 6,550 new cases, affecting both children and adults, diagnosed in the U.S. in 2024. 1 B-ALL begins in immature cells that would normally develop into B-cell lymphocytes, which are white blood cells that grow in bone marrow. 2,3 B-ALL is the most common type of ALL, constituting approximately 75% of cases in adults and approximately 88% in children, the most common cancer in children. 4,5 About BLINCYTO ® (blinatumomab) BLINCYTO is the first globally approved Bispecific T-cell Engager (BiTE ® ) immuno-oncology therapy that targets CD19 surface antigens on B cells. BiTE ® molecules fight cancer by helping the body's immune system detect and target malignant cells by engaging T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. By bringing T cells near cancer cells, the T cells can inject toxins and trigger cancer cell death (apoptosis). BiTE ® immuno-oncology therapies are currently being investigated for their potential to treat a wide variety of cancers. BLINCYTO was granted Breakthrough Therapy and Priority Review designations by the U.S. FDA and is approved in the U.S. for the treatment of: Adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-ALL during the consolidation phase of multiphase therapy. CD19-positive B-ALL in first or second complete remission with MRD greater than or equal to 0.1% in adults and pediatric patients one month or older. Relapsed or refractory CD19-positive B-ALL in adults and pediatric patients one month or older. In the European Union (EU), BLINCYTO is indicated as monotherapy for the treatment of: Adults with Philadelphia chromosome-negative CD19-positive relapsed or refractory B-ALL. Patients with Philadelphia chromosome-positive B-ALL should have failed treatment with at least two tyrosine kinase inhibitors (TKIs) and have no alternative treatment options. Adults with Philadelphia chromosome-negative CD19-positive B-ALL in first or second complete remission with MRD greater than or equal to 0.1%. Pediatric patients aged 1 year or older with Philadelphia chromosome-negative CD19-positive B-ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation. Pediatric patients aged 1 year or older with high-risk first relapsed Philadelphia chromosome-negative CD19-positive B-ALL as part of the consolidation therapy. BLINCYTO ® IMPORTANT SAFETY INFORMATION WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO ® . Interrupt or discontinue BLINCYTO ® and treat with corticosteroids as recommended. Neurological toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS) which may be severe, life-threatening, or fatal, occurred in patients receiving BLINCYTO ® . Interrupt or discontinue BLINCYTO ® as recommended. Contraindications BLINCYTO ® is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation. Warnings and Precautions Cytokine Release Syndrome (CRS): CRS, which may be life-threatening or fatal, occurred in patients receiving BLINCYTO ® . The median time to onset of CRS is 2 days after the start of infusion and the median time to resolution of CRS was 5 days among cases that resolved. Closely monitor and advise patients to contact their healthcare professional for signs and symptoms of serious adverse events such as fever, headache, nausea, asthenia, hypotension, increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), increased total bilirubin (TBILI), and disseminated intravascular coagulation (DIC). The manifestations of CRS after treatment with BLINCYTO ® overlap with those of infusion reactions, capillary leak syndrome (CLS), and hemophagocytic histiocytosis/macrophage activation syndrome (MAS). Using all of these terms to define CRS in clinical trials of BLINCYTO ® , CRS was reported in 15% of patients with R/R ALL, in 7% of patients with MRD-positive ALL, and in 16% of patients receiving BLINCYTO ® cycles in the consolidation phase of therapy. If severe CRS occurs, interrupt BLINCYTO ® until CRS resolves. Discontinue BLINCYTO ® permanently if life-threatening CRS occurs. Administer corticosteroids for severe or life-threatening CRS. Neurological Toxicities, including Immune Effector Cell-Associated Neurotoxicity Syndrome: BLINCYTO ® can cause serious or life-threatening neurologic toxicity, including ICANS. The incidence of neurologic toxicities in clinical trials was approximately 65%. The median time to the first event was within the first 2 weeks of BLINCYTO ® treatment. The most common (≥ 10%) manifestations of neurological toxicity were headache and tremor. Grade 3 or higher neurological toxicities occurred in approximately 13% of patients, including encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and disorientation, and coordination and balance disorders. Manifestations of neurological toxicity included cranial nerve disorders. The majority of neurologic toxicities resolved following interruption of BLINCYTO ® , but some resulted in treatment discontinuation. The incidence of signs and symptoms consistent with ICANS in clinical trials was 7.5%. The onset of ICANS can be concurrent with CRS, following resolution of CRS, or in the absence of CRS. There is limited experience with BLINCYTO ® in patients with active ALL in the central nervous system (CNS) or a history of neurologic events. Patients with a history or presence of clinically relevant CNS pathology were excluded from clinical studies. Patients with Down Syndrome over the age of 10 years may have a higher risk of seizures with BLINCYTO ® therapy. Monitor patients for signs and symptoms of neurological toxicities, including ICANS, and interrupt or discontinue BLINCYTO ® as outlined in the PI. Advise outpatients to contact their healthcare professional if they develop signs or symptoms of neurological toxicities. Infections: Approximately 25% of patients receiving BLINCYTO ® in clinical trials experienced serious infections such as sepsis, pneumonia, bacteremia, opportunistic infections, and catheter-site infections, some of which were life-threatening or fatal. Administer prophylactic antibiotics and employ surveillance testing as appropriate during treatment. Monitor patients for signs or symptoms of infection and treat appropriately, including interruption or discontinuation of BLINCYTO ® as needed. Tumor Lysis Syndrome (TLS), which may be life-threatening or fatal, has been observed. Preventive measures, including pretreatment nontoxic cytoreduction and on-treatment hydration, should be used during BLINCYTO ® treatment. Monitor patients for signs and symptoms of TLS and interrupt or discontinue BLINCYTO ® as needed to manage these events. Neutropenia and Febrile Neutropenia, including life-threatening cases, have been observed. Monitor appropriate laboratory parameters (including, but not limited to, white blood cell count and absolute neutrophil count) during BLINCYTO ® infusion and interrupt BLINCYTO ® if prolonged neutropenia occurs. Effects on Ability to Drive and Use Machines: Due to the possibility of neurological events, including seizures and ICANS, patients receiving BLINCYTO ® are at risk for loss of consciousness, and should be advised against driving and engaging in hazardous occupations or activities such as operating heavy or potentially dangerous machinery while BLINCYTO ® is being administered. Elevated Liver Enzymes: Transient elevations in liver enzymes have been associated with BLINCYTO ® treatment with a median time to onset of 3 days. In patients receiving BLINCYTO ® , although the majority of these events were observed in the setting of CRS, some cases of elevated liver enzymes were observed outside the setting of CRS, with a median time to onset of 19 days. Grade 3 or greater elevations in liver enzymes occurred in approximately 7% of patients outside the setting of CRS and resulted in treatment discontinuation in less than 1% of patients. Monitor ALT, AST, gamma-glutamyl transferase, and total blood bilirubin prior to the start of and during BLINCYTO ® treatment. BLINCYTO ® treatment should be interrupted if transaminases rise to > 5 times the upper limit of normal (ULN) or if total bilirubin rises to > 3 times ULN. Pancreatitis: Fatal pancreatitis has been reported in patients receiving BLINCYTO ® in combination with dexamethasone in clinical trials and the post-marketing setting. Evaluate patients who develop signs and symptoms of pancreatitis and interrupt or discontinue BLINCYTO ® and dexamethasone as needed. Leukoencephalopathy: Although the clinical significance is unknown, cranial magnetic resonance imaging (MRI) changes showing leukoencephalopathy have been observed in patients receiving BLINCYTO ® , especially in patients previously treated with cranial irradiation and antileukemic chemotherapy. Preparation and administration errors have occurred with BLINCYTO ® treatment. Follow instructions for preparation (including admixing) and administration in the PI strictly to minimize medication errors (including underdose and overdose). Immunization: Vaccination with live virus vaccines is not recommended for at least 2 weeks prior to the start of BLINCYTO ® treatment, during treatment, and until immune recovery following last cycle of BLINCYTO ® . Benzyl Alcohol Toxicity in Neonates: Serious adverse reactions, including fatal reactions and the "gasping syndrome," have been reported in very low birth weight (VLBW) neonates born weighing less than 1500 g, and early preterm neonates (infants born less than 34 weeks gestational age) who received intravenous drugs containing benzyl alcohol as a preservative. Early preterm VLBW neonates may be more likely to develop these reactions, because they may be less able to metabolize benzyl alcohol. Use the preservative-free preparations of BLINCYTO ® where possible in neonates. When prescribing BLINCYTO ® (with preservative) for neonatal patients, consider the combined daily metabolic load of benzyl alcohol from all sources including BLINCYTO ® (with preservative), other products containing benzyl alcohol or other excipients (e.g., ethanol, propylene glycol) which compete with benzyl alcohol for the same metabolic pathway. Monitor neonatal patients receiving BLINCYTO ® (with preservative) for new or worsening metabolic acidosis. The minimum amount of benzyl alcohol at which serious adverse reactions may occur in neonates is not known. The BLINCYTO ® 7-Day bag (with preservative) contains 7.4 mg of benzyl alcohol per mL. Embryo-Fetal Toxicity: Based on its mechanism of action, BLINCYTO ® may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with BLINCYTO ® and for 48 hours after the last dose. Adverse Reactions The safety of BLINCYTO ® in adult and pediatric patients one month and older with MRD-positive B-cell precursor ALL (n=137), relapsed or refractory B-cell precursor ALL (n=267), and Philadelphia chromosome-negative B-cell precursor ALL in consolidation (n=165) was evaluated in clinical studies. The most common adverse reactions (≥ 20%) to BLINCYTO ® in this pooled population were pyrexia, infusion-related reactions, headache, infection, musculoskeletal pain, neutropenia, nausea, anemia, thrombocytopenia, and diarrhea. Dosage and Administration Guidelines BLINCYTO ® is administered as a continuous intravenous infusion at a constant flow rate using an infusion pump which should be programmable, lockable, non-elastomeric, and have an alarm. It is very important that the instructions for preparation (including admixing) and administration provided in the full Prescribing Information are strictly followed to minimize medication errors (including underdose and overdose). INDICATIONS BLINCYTO ® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with: Philadelphia chromosome-negative disease in the consolidation phase of multiphase chemotherapy. Minimal residual disease (MRD) greater than or equal to 0.1% in first or second complete remission. Relapsed or refractory disease. Please see BLINCYTO ® full Prescribing Information , including BOXED WARNINGS. About Bispecific T-Cell Engager (BiTE ® ) Technology BiTE technology is a targeted immuno-oncology platform that is designed to engage a patient's own T cells to any tumor-specific antigen, activating the cytotoxic potential of T cells to eliminate detectable cancer. The BiTE immuno-oncology platform has the potential to treat different cancer types through tumor-specific antigens. The BiTE platform has a goal of leading to off-the-shelf solutions, which have the potential to make innovative T-cell treatment available to all providers when their patients need it. For more than a decade, Amgen has been advancing this innovative technology, which has demonstrated strong efficacy in hematological malignancies and now a solid tumor with the approval of IMDELLTRA. Amgen remains committed to progressing multiple BiTE molecules across a broad range of hematologic and solid tumor malignancies, paving the way for additional applications in more tumor types. Amgen is further investigating BiTE technology with the goal of enhancing patient experience and therapeutic potential. To learn more about BiTE technology, visit BiTE ® Technology 101 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), Amgen's acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on Amgen's acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on Amgen's business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including its most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints Amgen has selected. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with its products, including its devices, after they are on the market. Amgen's results may be affected by its ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions. In addition, sales of Amgen's products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen's research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen's business may be impacted by government investigations, litigation and product liability claims. In addition, Amgen's business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, Amgen could become subject to significant sanctions. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depends on third parties for a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for Amgen's manufacturing activities, the distribution of Amgen's products, the commercialization of Amgen's product candidates, and Amgen's clinical trial operations, and any such events may have a material adverse effect on Amgen's product development, product sales, business and results of operations. Amgen relies on collaborations with third parties for the development of some of its product candidates and for the commercialization and sales of some of its commercial products. In addition, Amgen competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for Amgen's products are supplied by sole third-party suppliers. Certain of Amgen's distributors, customers and payers have substantial purchasing leverage in their dealings with Amgen. The discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on its business and results of operations. Amgen's efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology Amgen has acquired, may not be successful. There can be no guarantee that Amgen will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. Amgen may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of Amgen's information technology systems could compromise the confidentiality, integrity and availability of Amgen's systems and Amgen's data. Amgen's stock price may be volatile and may be affected by a number of events. Amgen's business and operations may be negatively affected by the failure, or perceived failure, of achieving its environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect Amgen's business and operations. Global economic conditions may magnify certain risks that affect Amgen's business. Amgen's business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all. Any scientific information discussed in this news release relating to new indications for Amgen's products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) References National Institute of Health. Cancer Stat Facts: Leukemia — Acute Lymphocytic Leukemia (ALL). Available at: https://seer.cancer.gov/statfacts/html/alyl.html . Accessed on October 28, 2024 . Terwilliger T, et al. Blood Cancer J . 2017;7(6):e577. American Cancer Society. What is Acute Lymphocytic Leukemia (ALL)? Available at: https://www.cancer.org/cancer/types/acute-lymphocytic-leukemia/about/what-is-all.html . Accessed on October 28, 2024 . Leukemia & Lymphoma Society. Acute Lymphoblastic Leukemia (ALL). Available at: https://www.lls.org/research/acute-lymphoblastic-leukemia-all . Accessed on October 28, 2024 . National Cancer Institute. Childhood Acute Lymphoblastic Leukemia (PDQ ® )–Patient Version. Available at: https://www.cancer.gov/types/leukemia/patient/child-all-treatment-pdq . Accessed on November 19, 2024 . View original content to download multimedia: https://www.prnewswire.com/news-releases/blincyto-blinatumomab-added-to-chemotherapy-significantly-improves-survival-in-newly-diagnosed-pediatric-patients-with-b-cell-precursor-acute-lymphoblastic-leukemia-b-all-302325381.html SOURCE AmgenBy Jeff Mason and Steve Holland PALM BEACH, Florida (Reuters) - In his first news conference since his election victory six weeks ago, President-elect Donald Trump covered the Ukraine war, mysterious drones flying over New Jersey, the future of TikTok and lawsuits aimed at the media he often loves to hate. Trump displayed the loquaciousness and bravado of his 2017-2021 White House years as he held court in an ornate room at his Mar-a-Lago resort in Florida on Monday, making an economic announcement and fielding questions for more than an hour. He bantered with reporters, a departure from the dark rhetoric and anger he often flashed on the campaign trail. He answered questions about Ukraine and Israel, but declined to say whether he had spoken to Russian President Vladimir Putin or whether he would support military strikes on Iran. He seemed wiser to the ways of Washington and pleased, if a little bit puzzled, about his own new place in it, marveling at the steady procession of foreign leaders wanting to congratulate him and corporate CEOs rushing to meet with him. "The first term, everybody was fighting me," he said. "In this term, everybody wants to be my friend. I don’t know — my personality changed or something.” Trump's return to the White House on Jan. 20 comes at a time of deep polarization in the country and is likely to test democratic institutions at home and relations abroad. Advisers say he has been focused on choosing members of his Cabinet and his broader team who are expected to carry out his plans to dramatically overhaul government and U.S. policy. Since his Nov. 5 victory, Trump has not held one of his signature rallies or spoken at length to reporters, communicating instead through social media posts and the occasional speech. On Monday, however, he had good economic news to announce. With SoftBank Group CEO Masayoshi Son at his side, Trump said the Japanese technology company would invest $100 billion in the U.S. over the next four years. But that was just the warm-up act for the main event. Standing in front of the Trump coat of arms, the president-elect outlined some of his priorities for his second term, criticized President Joe Biden's outgoing administration and defended some of his own controversial cabinet picks. The lengthy back and forth marked a contrast with Biden, who rarely holds news conferences. 'GOTTA MAKE A DEAL' Trump predicted his choice for Health and Human Services secretary, Robert F. Kennedy Jr., would be "much less radical than you think" but waxed on about whether there is a link between vaccines and autism while saying he supports the polio vaccine. Studies have found no links between vaccines and autism. Trump said "it would be a tragedy" if his choice for defense secretary, former Fox News personality Pete Hegseth, does not make it to Senate confirmation amid concerns about allegations of misconduct in his professional and personal life. He spoke about the possibility of issuing a pardon to New York City Mayor Eric Adams and said he thought it was possible to eliminate $2 trillion in government spending through the Elon Musk-led government efficiency project. He said his administration will "take a look" at whether the Chinese-owned social media app TikTok should be banned in the U.S. and encouraged the U.S. military to tell the American public more about the nature of the drone sightings that have plagued the East Coast over the last several weeks. Trump also veered into personal grievances, vowing to file lawsuits against multiple media companies that he felt have abused him. "Now you need fair elections, you need borders, and you need a fair press," Trump said, touching on some of his favorite grievance-related topics. "Our press is very corrupt. Almost as corrupt as our elections." That interlude aside, Trump spent most of his time talking about foreign policy and the economy. Of the world's two biggest hotspots, he was blunt: Hamas needs to reach a deal with Israel releasing the remaining hostages it is holding in Gaza, or face the consequences. If no ceasefire deal is reached by the time he takes office, Trump said, "it's not going to be pleasant." He also said Ukraine President Volodymyr Zelenskiy should be prepared to make a deal with Russian President Vladimir Putin to bring an end to the nearly three-year-old Ukraine war. "Gotta make a deal," Trump said. (Reporting by Jeff Mason and Steve Holland; Editing by Colleen Jenkins and Lincoln Feast.)